TMED9 is a Predictive Marker of Transition from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

Purpose: Plasma Cell Dyscrasias are a heterogeneous group of hematological diseases. The candidate ten genes identified from our transcriptome data are highly valuable and specific. Methods: We investigated the prognostic biomarker status of these genes in Plasma Cell Dyscrasias. Expression levels of ISG20, EEF2, TRIB1, RRBP1, TMED9, KDELR1, DNAJC1, DPP7, COPE and LMAN2 genes were measured via qRT-PCR from bone marrow samples of 38 Multiple Myeloma, 23 MGUS and 16 control groups. Results: According to our results, in the Multiple Myeloma group, all genes were more highly expressed than control and MGUS groups (pDNAJC1 is an important risk factor for MM (pTMED9 gene expression and clinical parameters of urea, Ca, albumin, LDH, and IGA levels (pTMED9gene in our results sheds light on myeloma genesis. Conclusion: This study contributed significantly to the search on prognostic biomarkers for Multiple Myeloma progression from MGUS and for starting early treatment in MGUS.